United BioSource Corporation Acquires DataPhase IV Inc.
United BioSource Corp., formed in 2003 to provide science- and evidence-based services and information to the pharmaceutical and life sciences industries, announced that it has acquired DataPhase IV, Inc., a Morgantown, W.V.-based provider of information systems and telecommunications services for post-marketing surveillance, pharmacovigilance, and risk management of pharmaceutical products.
The acquisition is the second to be announced since the Washington-based United BioSource Corp. raised $153 million in equity capital from a syndicate of leading private equity firms. The company acquired MEDTAP International, a provider of health economics and outcomes research services, in January 2004. Terms of the DataPhase IV acquisition were not disclosed.
DataPhase IV, Inc. (DPIV) is a privately held company with programs operating in North America and the European Union. Since 1998, DPIV has assisted pharmaceutical companies with every aspect of their post-marketing surveillance and risk-management needs. With state-of-the-art data collection and management services, large-scale call center services and highly experienced project management resources, DPIV develops and manages some of the most complex and stringent risk-management programs ever launched.
“We are proud to bring DataPhase IV on board as the latest core asset of our company, as it has an outstanding record of successfully developing and executing complex post- marketing surveillance and risk-management programs,” said Ethan Leder, CEO of United BioSource Corp. “DataPhase IV’s post-marketing capabilities are important, given the increasing pressure on pharmaceutical companies to monitor the performance and safety of their products in real-world situations, particularly among at-risk Medicare and Medicaid populations.”
“The effective collection and management of complex post-marketing data is becoming increasingly important among the largest health care payers such as Medicaid and Medicare,” said Ruben J. King-Shaw, Jr, President of UBC Solutions, the division of United BioSource dedicated to identifying solutions that improve patient outcomes and effectively manage the costs of pharmaceutical therapies. “With the acquisition of Dataphase IV, UBC Solutions now offers payers and industry cutting-edge post-marketing data management capabilities,” continued King-Shaw, “this is an important advantage as we work to improve the management of patients and the appropriate use of pharmaceutical therapies in Medicaid and Medicare populations.”
DPIV will operate as a wholly owned subsidiary of United BioSource, and will remain headquartered in Morgantown. Chad Clark, founder of DPIV, will continue his leadership role within the company. “We expect to grow our investment in Morgantown,” Clark said. “The city, along with the West Virginia High Technology Consortium Foundation in I-79 Technology Park, provides a favorable environment for expanding our technology-driven operation.
“The DPIV team has been impressed with United BioSource’s dedication to scientific, evidence-based approaches to health care,” Clark said. “With the support of United BioSource, DPIV will be able to increase our presence in the market for post- marketing, safety, and pharmacovigilance services.”
About DataPhase IV, Inc.
DataPhase IV, Inc. provides post-marketing surveillance, pharmacovigilance and risk- management services to the pharmaceutical industry.
About United BioSource Corporation
United BioSource was formed in 2003 to provide science- and evidence based services and information to the pharmaceutical and life sciences industries.
For more information about United BioSource Corp., visit www.unitedbiosource.com or call 202-457-1900.
